✦ LIBER ✦

Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer

✍ Scribed by John W. Smith; Kristi J. McIntyre; Patrick V. Acevedo; Carlos A. Encarnacion; Karen L. Tedesco; Yunfei Wang; Lina Asmar; Joyce A. O’Shaughnessy

Publisher: Springer US
Year: 2009
Tongue: English
Weight: 230 KB
Volume: 118
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-009-0410-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II trial of oral temozolomide in

A phase II trial of oral temozolomide in patients with metastatic renal cell cancer

✍ D. Park; C. Ryan; M. Dolan; N. Vogelzang; W. Stadler 📂 Article 📅 2002 🏛 Springer 🌐 English ⚖ 62 KB

A phase II trial of imatinib mesylate mo

A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer

✍ Shanu Modi; Andrew D. Seidman; Maura Dickler; Mark Moasser; Gabriella D’Andrea; 📂 Article 📅 2005 🏛 Springer US 🌐 English ⚖ 255 KB

A phase I trial of oral metronomic vinor

A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer

✍ Zacharenia Saridaki; Nikolaos Malamos; Panagiotis Kourakos; Aristides Polyzos; A 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 294 KB

Phase II trial of edatrexate in patients

Phase II trial of edatrexate in patients with metastatic colorectal cancer

✍ Gerald H. Clamon; Charles E. Riggs; Robert Dreicer; Raymond J. Hohl 📂 Article 📅 1995 🏛 Springer US 🌐 English ⚖ 242 KB

Carboplatin activity in untreated metast

Carboplatin activity in untreated metastatic breast cancer patients — results of a phase II study

✍ K. Kolarić; D. Vukas 📂 Article 📅 1991 🏛 Springer 🌐 English ⚖ 388 KB

Phase II study of ionidamine in patients

Phase II study of ionidamine in patients with metastatic breast cancer

✍ H. Ian Robins; Donna S. Neuberg; Al B. Benson; Kishan J. Pandya; Douglass C. Tor 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 193 KB

The Eastern Cooperative Oncology Group conducted a phase II study of lonidamine in patients with metastatic breast cancer. The drug was given orally to a maximum daily dose of 340 mg/m 2. Forty-two patients were entered on study. One partial response was observed; there were no life-threatening toxi